--- title: "RCKT 最後期限：Rosen 律師事務所敦促 Rocket 製藥公司（NASDAQ: RCKT）的股東，如果損失超過 10 萬美元，請聯繫該事務所以瞭解他們的權利信息" description: "Rosen 律師事務所呼籲 Rocket Pharmaceuticals, Inc.（納斯達克代碼：RCKT）的股東，如果他們的損失超過 10 萬美元，請與他們聯繫以瞭解自己的權利。針對在 2024 年 9 月 17 日至 2025 年 5 月 26 日期間購買證券的投資者，已提起集體訴訟，指控該公司誤導投資者關於其 RP-A501 治療的有效性和安全性。希望領導該集體訴訟的股東必須在 2025 " type: "news" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/251303959.md" published_at: "2025-08-02T21:25:32.000Z" --- # RCKT 最後期限：Rosen 律師事務所敦促 Rocket 製藥公司（NASDAQ: RCKT）的股東，如果損失超過 10 萬美元，請聯繫該事務所以瞭解他們的權利信息 > Rosen 律師事務所呼籲 Rocket Pharmaceuticals, Inc.（納斯達克代碼：RCKT）的股東，如果他們的損失超過 10 萬美元，請與他們聯繫以瞭解自己的權利。針對在 2024 年 9 月 17 日至 2025 年 5 月 26 日期間購買證券的投資者，已提起集體訴訟，指控該公司誤導投資者關於其 RP-A501 治療的有效性和安全性。希望領導該集體訴訟的股東必須在 2025 年 8 月 11 日之前提交動議。Rosen 律師事務所以風險代理費用的方式運營，確保股東無需支付前期費用 **RCKT Deadline: Rosen Law Firm Urges Rocket Pharmaceuticals,** **Inc. (NASDAQ: RCKT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights** Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action lawsuit on behalf of purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between September 17, 2024 and May 26, 2025. Rocket Pharmaceuticals is a fully integrated, late-stage biotechnology company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) Misled Investors Regarding its Business Operations. According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) RP-A501 was less effective than defendants had led investors to believe; (2) to increase its effectiveness, Rocket Pharmaceuticals amended RP-A501’s clinical trial protocol by introducing a novel immunomodulatory agent; (3) the foregoing increased the risk that patients would suffer from a Serious Adverse Event (“SAE”); (4) accordingly, RP-A501’s safety, as well as its clinical, regulatory, and commercial prospects, were overstated; and (5) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. What Now: You may be eligible to participate in the class action against Rocket Pharmaceuticals, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by August 11, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen\_firm or on Facebook: https://www.facebook.com/rosenlawfirm/. Attorney Advertising. Prior results do not guarantee a similar outcome. Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 case@rosenlegal.com www.rosenlegal.com View source version on businesswire.com: https://www.businesswire.com/news/home/20250802688652/en/ ### Related Stocks - [RCKT.US - Rocket制藥](https://longbridge.com/zh-HK/quote/RCKT.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Rokt 參與美國心臟協會的 “Go Red. Shop with Heart” 計劃，並在紐約證券交易所的敲鐘儀式上正式啓動 | Rokt 是一家領先的電子商務技術公司，已加入美國心臟協會的 “Go Red. Shop with Heart” 倡議，旨在提高人們對心臟健康的認識並籌集資金，活動將在二月份的美國心臟月期間進行。該活動在紐約證券交易所舉行了鳴鐘儀式，Rok | [Link](https://longbridge.com/zh-HK/news/275145288.md) | | Rocket Doctor AI 向顧問授予股票期權和限制性股票單位 | Rocket Doctor AI Inc. 已向顧問授予 33,353 份股票期權，價格為每股 0.77 美元，以及 205,065 份限制性股票單位，均有效期為三年。這些都是公司股票薪酬計劃的一部分，將在一年內歸屬。該公告於 2026 年 | [Link](https://longbridge.com/zh-HK/news/274366738.md) | | Rocket Doctor 與 Danayi Capital 合作進行數字營銷服務 \| AIRDF 股票新聞 | Rocket Doctor AI Inc. 已與 Danayi Capital Corp. 簽訂了為期兩個月的數字營銷服務合同，合同自 2026 年 2 月 9 日開始，預付款為 125,000 美元。此外，公司還向顧問授予了 33,353 | [Link](https://longbridge.com/zh-HK/news/274367082.md) | | Rocket Doctor AI 與美國一家主要保險公司簽署了網絡內合同，覆蓋加州的 17.5 萬名會員 | Rocket Doctor AI Inc. 與一家主要的美國保險公司簽署了合同，將其數字健康平台擴展至加利福尼亞州的 175,000 名額外成員。此協議使 Rocket Doctor 在美國的網絡覆蓋人數增加到超過 1300 萬，主要集中在 | [Link](https://longbridge.com/zh-HK/news/273874717.md) | | Wedbush 重申了他們對 Rocket 製藥（RCKT）的買入評級 | Wedbush 分析師 Yun Zhong 重申了對 Rocket Pharmaceuticals (RCKT) 的買入評級，目標價為 16.00 美元。Zhong 的平均回報為 -9.0%，成功率為 42.50%，同時他也覆蓋其他醫療保健 | [Link](https://longbridge.com/zh-HK/news/264863677.md) | --- > **免責聲明**：本文內容僅供參考，不構成任何投資建議。